In addition, we have found that inhibitors combined with topotecan significantly decreased expression levels of phosphorylated p65 (NF-kB) and S6K (mTOR) pathways molecules in MYCN-amplified cells but not in non-MYCN-amplified neuroblastoma cells, indicating further activity of inhibitors in aggressive MYCN-amplified cells (Figure 5). This evidence concerns the gene RPS6KB1 and neuroblastoma.